Statin prescribing guide /:
The first HMG-CoA reductase inhibitor (statin), lovastatin, has been on the market since 1987. In that time, five more drugs from this class, atorvastatin, pravastatin, fluvastatin, rosuvastatin and simvastatin, have been approved by the FDA. Statins, among the top ten most commonly prescribed drugs...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Oxford ; New York :
Oxford University Press,
©2010.
|
| Schriftenreihe: | Oxford American pocket notes.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | The first HMG-CoA reductase inhibitor (statin), lovastatin, has been on the market since 1987. In that time, five more drugs from this class, atorvastatin, pravastatin, fluvastatin, rosuvastatin and simvastatin, have been approved by the FDA. Statins, among the top ten most commonly prescribed drugs in the U.S., are now recommended as first-line treatments by all major regulatory agencies in the U.S. and elsewhere. As shown in numerous clinical trials, statins are extremely powerful and effective in reducing LDL cholesterol, accompanied by a significant reduction of cardiac events and strokes. |
| Beschreibung: | 1 online resource (75 pages) : illustrations |
| Bibliographie: | Includes bibliographical references (pages 65-68). |
| ISBN: | 9780199780129 0199780129 1282946757 9781282946750 9786612946752 661294675X |
Internformat
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn695030270 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 110105s2010 enka ob 000 0 eng d | ||
| 040 | |a N$T |b eng |e pn |c N$T |d E7B |d OCLCQ |d YDXCP |d OCLCQ |d OCLCF |d NLGGC |d EBLCP |d Z5A |d OCLCQ |d AGLDB |d STF |d OCLCQ |d VTS |d M8D |d OCLCQ |d VLY |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d OCLCL | ||
| 019 | |a 651602029 |a 1162524671 |a 1241858794 |a 1300527330 | ||
| 020 | |a 9780199780129 |q (electronic bk.) | ||
| 020 | |a 0199780129 |q (electronic bk.) | ||
| 020 | |a 1282946757 | ||
| 020 | |a 9781282946750 | ||
| 020 | |a 9786612946752 | ||
| 020 | |a 661294675X | ||
| 020 | |z 9780195392340 | ||
| 020 | |z 0195392345 | ||
| 035 | |a (OCoLC)695030270 |z (OCoLC)651602029 |z (OCoLC)1162524671 |z (OCoLC)1241858794 |z (OCoLC)1300527330 | ||
| 050 | 4 | |a RM666.S714 |b .B35 2010eb | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 082 | 7 | |a 615.718 |2 22 | |
| 049 | |a MAIN | ||
| 100 | 1 | |a Baliga, R. R. |0 http://id.loc.gov/authorities/names/n94035544 | |
| 245 | 1 | 0 | |a Statin prescribing guide / |c by Ragavendra R. Baliga. |
| 260 | |a Oxford ; |a New York : |b Oxford University Press, |c ©2010. | ||
| 300 | |a 1 online resource (75 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Oxford American pocket notes | |
| 504 | |a Includes bibliographical references (pages 65-68). | ||
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a Table of Contents; 1. Introduction; 2. History; 3. Fredrickson Classification of Hyperlipoproteinemias; 4. Risk Assessment and the NCEP/ATP-III Nine-Step Approach to Dyslipidemia; 5. Statins Mechanism of Action; 6. Pharmacokinetic Properties; 7. Dyslipidemia, Statins, and Cardiovascular Risk; 8. Intensive Versus Standard Statin Therapy; 9. Complications, Contraindications, and Side Effects; 10. Drug Interactions; 11. Statin Dosage and Administration Guidelines; 12. Special Groups; 13. Drug Combinations; 14. Final Conclusions; 15. References; 16. Appendix. | |
| 520 | |a The first HMG-CoA reductase inhibitor (statin), lovastatin, has been on the market since 1987. In that time, five more drugs from this class, atorvastatin, pravastatin, fluvastatin, rosuvastatin and simvastatin, have been approved by the FDA. Statins, among the top ten most commonly prescribed drugs in the U.S., are now recommended as first-line treatments by all major regulatory agencies in the U.S. and elsewhere. As shown in numerous clinical trials, statins are extremely powerful and effective in reducing LDL cholesterol, accompanied by a significant reduction of cardiac events and strokes. | ||
| 546 | |a English. | ||
| 650 | 0 | |a Statins (Cardiovascular agents) |0 http://id.loc.gov/authorities/subjects/sh00001691 | |
| 650 | 0 | |a Drugs |x Prescribing. |0 http://id.loc.gov/authorities/subjects/sh85039743 | |
| 650 | 2 | |a Drug Prescriptions |0 https://id.nlm.nih.gov/mesh/D011307 | |
| 650 | 6 | |a Statines. | |
| 650 | 6 | |a Médicaments |x Prescription. | |
| 650 | 7 | |a prescriptions. |2 aat | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Drugs |x Prescribing |2 fast | |
| 650 | 7 | |a Statins (Cardiovascular agents) |2 fast | |
| 758 | |i has work: |a Statin prescribing guide (Text) |1 https://id.oclc.org/worldcat/entity/E39PCH49FkR4QbRMD7f7jTBdHy |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Baliga, R.R. |t Statin prescribing guide. |d Oxford ; New York : Oxford University Press, ©2010 |z 9780195392340 |w (OCoLC)660510129 |
| 830 | 0 | |a Oxford American pocket notes. |0 http://id.loc.gov/authorities/names/no2010038979 | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=350190 |3 Volltext |
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL555334 | ||
| 938 | |a ebrary |b EBRY |n ebr10437707 | ||
| 938 | |a EBSCOhost |b EBSC |n 350190 | ||
| 938 | |a YBP Library Services |b YANK |n 3384831 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn695030270 |
|---|---|
| _version_ | 1816881748236042240 |
| adam_text | |
| any_adam_object | |
| author | Baliga, R. R. |
| author_GND | http://id.loc.gov/authorities/names/n94035544 |
| author_facet | Baliga, R. R. |
| author_role | |
| author_sort | Baliga, R. R. |
| author_variant | r r b rr rrb |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RM666 |
| callnumber-raw | RM666.S714 .B35 2010eb |
| callnumber-search | RM666.S714 .B35 2010eb |
| callnumber-sort | RM 3666 S714 B35 42010EB |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| collection | ZDB-4-EBA |
| contents | Table of Contents; 1. Introduction; 2. History; 3. Fredrickson Classification of Hyperlipoproteinemias; 4. Risk Assessment and the NCEP/ATP-III Nine-Step Approach to Dyslipidemia; 5. Statins Mechanism of Action; 6. Pharmacokinetic Properties; 7. Dyslipidemia, Statins, and Cardiovascular Risk; 8. Intensive Versus Standard Statin Therapy; 9. Complications, Contraindications, and Side Effects; 10. Drug Interactions; 11. Statin Dosage and Administration Guidelines; 12. Special Groups; 13. Drug Combinations; 14. Final Conclusions; 15. References; 16. Appendix. |
| ctrlnum | (OCoLC)695030270 |
| dewey-full | 615.718 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.718 |
| dewey-search | 615.718 |
| dewey-sort | 3615.718 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03958cam a2200649 a 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn695030270</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu---unuuu</controlfield><controlfield tag="008">110105s2010 enka ob 000 0 eng d</controlfield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">N$T</subfield><subfield code="b">eng</subfield><subfield code="e">pn</subfield><subfield code="c">N$T</subfield><subfield code="d">E7B</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">YDXCP</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCF</subfield><subfield code="d">NLGGC</subfield><subfield code="d">EBLCP</subfield><subfield code="d">Z5A</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">AGLDB</subfield><subfield code="d">STF</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">VTS</subfield><subfield code="d">M8D</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">VLY</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCL</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">651602029</subfield><subfield code="a">1162524671</subfield><subfield code="a">1241858794</subfield><subfield code="a">1300527330</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780199780129</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0199780129</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1282946757</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781282946750</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9786612946752</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">661294675X</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9780195392340</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">0195392345</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)695030270</subfield><subfield code="z">(OCoLC)651602029</subfield><subfield code="z">(OCoLC)1162524671</subfield><subfield code="z">(OCoLC)1241858794</subfield><subfield code="z">(OCoLC)1300527330</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RM666.S714</subfield><subfield code="b">.B35 2010eb</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">071000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615.718</subfield><subfield code="2">22</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Baliga, R. R.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n94035544</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Statin prescribing guide /</subfield><subfield code="c">by Ragavendra R. Baliga.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Oxford ;</subfield><subfield code="a">New York :</subfield><subfield code="b">Oxford University Press,</subfield><subfield code="c">©2010.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (75 pages) :</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Oxford American pocket notes</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references (pages 65-68).</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Print version record.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Table of Contents; 1. Introduction; 2. History; 3. Fredrickson Classification of Hyperlipoproteinemias; 4. Risk Assessment and the NCEP/ATP-III Nine-Step Approach to Dyslipidemia; 5. Statins Mechanism of Action; 6. Pharmacokinetic Properties; 7. Dyslipidemia, Statins, and Cardiovascular Risk; 8. Intensive Versus Standard Statin Therapy; 9. Complications, Contraindications, and Side Effects; 10. Drug Interactions; 11. Statin Dosage and Administration Guidelines; 12. Special Groups; 13. Drug Combinations; 14. Final Conclusions; 15. References; 16. Appendix.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The first HMG-CoA reductase inhibitor (statin), lovastatin, has been on the market since 1987. In that time, five more drugs from this class, atorvastatin, pravastatin, fluvastatin, rosuvastatin and simvastatin, have been approved by the FDA. Statins, among the top ten most commonly prescribed drugs in the U.S., are now recommended as first-line treatments by all major regulatory agencies in the U.S. and elsewhere. As shown in numerous clinical trials, statins are extremely powerful and effective in reducing LDL cholesterol, accompanied by a significant reduction of cardiac events and strokes.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Statins (Cardiovascular agents)</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh00001691</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Drugs</subfield><subfield code="x">Prescribing.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh85039743</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Drug Prescriptions</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D011307</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Statines.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Médicaments</subfield><subfield code="x">Prescription.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">prescriptions.</subfield><subfield code="2">aat</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Pharmacology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drugs</subfield><subfield code="x">Prescribing</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Statins (Cardiovascular agents)</subfield><subfield code="2">fast</subfield></datafield><datafield tag="758" ind1=" " ind2=" "><subfield code="i">has work:</subfield><subfield code="a">Statin prescribing guide (Text)</subfield><subfield code="1">https://id.oclc.org/worldcat/entity/E39PCH49FkR4QbRMD7f7jTBdHy</subfield><subfield code="4">https://id.oclc.org/worldcat/ontology/hasWork</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="a">Baliga, R.R.</subfield><subfield code="t">Statin prescribing guide.</subfield><subfield code="d">Oxford ; New York : Oxford University Press, ©2010</subfield><subfield code="z">9780195392340</subfield><subfield code="w">(OCoLC)660510129</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Oxford American pocket notes.</subfield><subfield code="0">http://id.loc.gov/authorities/names/no2010038979</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=350190</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL555334</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ebrary</subfield><subfield code="b">EBRY</subfield><subfield code="n">ebr10437707</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">350190</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">3384831</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-ocn695030270 |
| illustrated | Illustrated |
| indexdate | 2024-11-27T13:17:39Z |
| institution | BVB |
| isbn | 9780199780129 0199780129 1282946757 9781282946750 9786612946752 661294675X |
| language | English |
| oclc_num | 695030270 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (75 pages) : illustrations |
| psigel | ZDB-4-EBA |
| publishDate | 2010 |
| publishDateSearch | 2010 |
| publishDateSort | 2010 |
| publisher | Oxford University Press, |
| record_format | marc |
| series | Oxford American pocket notes. |
| series2 | Oxford American pocket notes |
| spelling | Baliga, R. R. http://id.loc.gov/authorities/names/n94035544 Statin prescribing guide / by Ragavendra R. Baliga. Oxford ; New York : Oxford University Press, ©2010. 1 online resource (75 pages) : illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier Oxford American pocket notes Includes bibliographical references (pages 65-68). Print version record. Table of Contents; 1. Introduction; 2. History; 3. Fredrickson Classification of Hyperlipoproteinemias; 4. Risk Assessment and the NCEP/ATP-III Nine-Step Approach to Dyslipidemia; 5. Statins Mechanism of Action; 6. Pharmacokinetic Properties; 7. Dyslipidemia, Statins, and Cardiovascular Risk; 8. Intensive Versus Standard Statin Therapy; 9. Complications, Contraindications, and Side Effects; 10. Drug Interactions; 11. Statin Dosage and Administration Guidelines; 12. Special Groups; 13. Drug Combinations; 14. Final Conclusions; 15. References; 16. Appendix. The first HMG-CoA reductase inhibitor (statin), lovastatin, has been on the market since 1987. In that time, five more drugs from this class, atorvastatin, pravastatin, fluvastatin, rosuvastatin and simvastatin, have been approved by the FDA. Statins, among the top ten most commonly prescribed drugs in the U.S., are now recommended as first-line treatments by all major regulatory agencies in the U.S. and elsewhere. As shown in numerous clinical trials, statins are extremely powerful and effective in reducing LDL cholesterol, accompanied by a significant reduction of cardiac events and strokes. English. Statins (Cardiovascular agents) http://id.loc.gov/authorities/subjects/sh00001691 Drugs Prescribing. http://id.loc.gov/authorities/subjects/sh85039743 Drug Prescriptions https://id.nlm.nih.gov/mesh/D011307 Statines. Médicaments Prescription. prescriptions. aat MEDICAL Pharmacology. bisacsh Drugs Prescribing fast Statins (Cardiovascular agents) fast has work: Statin prescribing guide (Text) https://id.oclc.org/worldcat/entity/E39PCH49FkR4QbRMD7f7jTBdHy https://id.oclc.org/worldcat/ontology/hasWork Print version: Baliga, R.R. Statin prescribing guide. Oxford ; New York : Oxford University Press, ©2010 9780195392340 (OCoLC)660510129 Oxford American pocket notes. http://id.loc.gov/authorities/names/no2010038979 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=350190 Volltext |
| spellingShingle | Baliga, R. R. Statin prescribing guide / Oxford American pocket notes. Table of Contents; 1. Introduction; 2. History; 3. Fredrickson Classification of Hyperlipoproteinemias; 4. Risk Assessment and the NCEP/ATP-III Nine-Step Approach to Dyslipidemia; 5. Statins Mechanism of Action; 6. Pharmacokinetic Properties; 7. Dyslipidemia, Statins, and Cardiovascular Risk; 8. Intensive Versus Standard Statin Therapy; 9. Complications, Contraindications, and Side Effects; 10. Drug Interactions; 11. Statin Dosage and Administration Guidelines; 12. Special Groups; 13. Drug Combinations; 14. Final Conclusions; 15. References; 16. Appendix. Statins (Cardiovascular agents) http://id.loc.gov/authorities/subjects/sh00001691 Drugs Prescribing. http://id.loc.gov/authorities/subjects/sh85039743 Drug Prescriptions https://id.nlm.nih.gov/mesh/D011307 Statines. Médicaments Prescription. prescriptions. aat MEDICAL Pharmacology. bisacsh Drugs Prescribing fast Statins (Cardiovascular agents) fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh00001691 http://id.loc.gov/authorities/subjects/sh85039743 https://id.nlm.nih.gov/mesh/D011307 |
| title | Statin prescribing guide / |
| title_auth | Statin prescribing guide / |
| title_exact_search | Statin prescribing guide / |
| title_full | Statin prescribing guide / by Ragavendra R. Baliga. |
| title_fullStr | Statin prescribing guide / by Ragavendra R. Baliga. |
| title_full_unstemmed | Statin prescribing guide / by Ragavendra R. Baliga. |
| title_short | Statin prescribing guide / |
| title_sort | statin prescribing guide |
| topic | Statins (Cardiovascular agents) http://id.loc.gov/authorities/subjects/sh00001691 Drugs Prescribing. http://id.loc.gov/authorities/subjects/sh85039743 Drug Prescriptions https://id.nlm.nih.gov/mesh/D011307 Statines. Médicaments Prescription. prescriptions. aat MEDICAL Pharmacology. bisacsh Drugs Prescribing fast Statins (Cardiovascular agents) fast |
| topic_facet | Statins (Cardiovascular agents) Drugs Prescribing. Drug Prescriptions Statines. Médicaments Prescription. prescriptions. MEDICAL Pharmacology. Drugs Prescribing |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=350190 |
| work_keys_str_mv | AT baligarr statinprescribingguide |